Whether the changes in vascular insulin sensitivity we observed (individually or in aggregate) contribute meaningfully to the observed beneficial MACE, heart failure, or functional renal preservation seen in long-term, multicenter clinical trials cannot be adjudicated from the current small, 12-wk trial. Here, INS is linked to heart failure.